HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With ‘Significant Headroom For Growth,' Is Standalone Space Ahead For DSM Nutrition?

Executive Summary

DSM says its nutrition segment, which includes human and animal nutrition and personal care, has a “unique business model combining 'global products' and 'local solutions'” and showed 6% organic sales growth for 2020 and 8% for Q4.

You may also be interested in...



Royal DSM Fills Plate With Nutrition, Health And Bioscience, Plans To Slice Off Chemical Business

Sale is among options it’s considering for materials business, which is currently “managed largely on a standalone basis.” Its health, nutrition and bioscience segments account for 80% to 85% of total sales and will operate as individual business groups.

DSM Remodels Nutrition Business With Fundamental Piece – Cannabinoid Ingredients

Royal DSM and Colorado’s Mile High Labs partner to provide companies in supplement, food and beverage sectors with ingredients to develop formulations with CBD and other cannabinoids. They initially are targeting the US and look to enter Canada, South America, Europe and Australia.

Consumer Health Business News: Rebrands for Takeda OTC And Reckitt, DSM Acquires, Enzymatica Raises Funds

A round-up of the latest consumer health industry news: Takeda completes the sale of its Japanese OTC business, which has rebranded as Alinamin; Reckitt drops the "Benckiser" from its name to signal new approach; Enzymatica looks to raise funds as COVID continues to bite; and Royal DSM expands its portfolio through a new deal with Amyris. 

Related Content

Topics

UsernamePublicRestriction

Register

RS151020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel